First Cell-Based Gene Therapy Approved for Multiple Myeloma
Abecma indicated for patients with relapsed or refractory multiple myeloma who have received at least four previous types of therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.